Accelerate to discover

Back to filter

Related topics

The chicken chorioallantoic membrane as a low-cost, high-throughput model for cancer imaging

Precision X-Ray

Apr 4, 2024

Here, we assessed the chicken chorioallantoic membrane (CAM) as an alternative to mice for preclinical cancer imaging...

A microthrombus-driven fixed-point cleaved nanosystem for preventing post-thrombolysis recurrence

IVIM Technology

Apr 3, 2024

A thrombin-responsive and fixed-point cleaved Fu@pep-CLipo was developed for highly efficient and precise thrombolysis...

Webinar: Multimodal Assessment of Hypoxia in Tumors: From the Lab to the Clinic

Bruker Biospin

Apr 2, 2024

25 April 2024, 4PM CET
This webinar will be of interest to multiple profiles in the community of biomedical
...

Multiplexed tissue imaging using the Orion platform to reveal the Spatial Biology of Cancer

RareCyte

Mar 27, 2024

In this webinar Prof. Sandro Santagata, will reveal how Orion high-plex imaging and the use of this data, is valuable...

Apr 20, 2024

A 19-color single-tube Full Spectrum Flow Cytometry for the detection of Acute Myeloid Leukemia

Cytek Biosciences

Mar 13, 2024

This recent publication in Cytometry Part A describes the development and comprehensive workflow of a single-tube,...

18F-labeled somatostatin analogs for somatostatin receptors (SSTRs) targeted PET imaging of NETs

MOLECUBES

Mar 11, 2024

A novel 18F-radiolabeled somatostatin analogue, [Al18F]NODA-MPAA-HTA, was synthesized and evaluated for positron...

Discover Yokogawa CellVoyager CQ1: Benchtop High-Content Analysis System

Yokogawa

Mar 8, 2024

Unlike flow cytometers, the CellVoyager CQ1 confocal quantitative image cytometer does not require pretreatment such as...

Apr 20, 2024

Real-time and quantitative analysis of Macrophage Phagocytosis with RTCA eSight

Agilent technologies

Feb 23, 2024

The eSight is currently the only instrument that interrogates cell health and behavior using cellular
impedance
...

Show all topics (10)

Heterodimeric compounds with dual-targeting active against both HIV and tuberculosis.

Jun 4, 2018

Both HIV and Tuberculosis are considered to be one of the most dangerous infectious diseases in the world. Quite often these two pathogens work in synchrony, making the risk of patient´s death twice as high. To solve this problem researchers from the Engelhardt Institute of Molecular biology in Russia cooperated with the National Institute of Health in the USA. They created compounds with dual activity against both pathogens by creating a heterodimer based on nucleosides. These heterodimers have two active components with two different rates of release based on the speed of their hydrolysis. They tested five of such compounds on HIV and Tuberculosis strain MS-114, which is drug-resistance. Drug-resistance of tuberculosis is one of the main problems in the treatment nowadays.

The compounds were judged based on the ability to inhibit these pathogens. Additionally, a testing on the host tissue was done using NovoCyte. The researchers tested the viability of mammalian lymphoid tissue after treatment. The results show that the heterodimers are non-toxic and non-static towards the cells while maintaining the potency against the pathogens. So far the compound was tested in vivo and ex vitro and seem to be a very promising solution. These results bring interesting insight and novel approach toward treatment of both HIV and Tuberculosis.

Want to know more?

Scientific paper
Application

Related technologies: Conventional flow cytometry

Brand profile

Agilent technologies

Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

The best in class personalized flow cytometer

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey